Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

AURORA, Ontario, June 15 /PRNewswire/ -- Helix BioPharma Corp. ("Helix" or the "Company"), (TSX, FSE: "HBP") today announced its product development progress, quarterly highlights and financial results for the third quarter of fiscal 2009, ended April 30, 2009.

THIRD QUARTER HIGHLIGHTS AND PRODUCT DEVELOPMENT UPDATE

U.S. Registration Statement

Helix's 20-F registration statement filed with the U.S. Securities and Exchange Commission became effective during the quarter.

BioFinance 2009 Investor Conference Presentation

John Docherty, president and chief operating officer, presented at the BioFinance 2009 Investor Conference, where he provided an overview of the Company's leading technology platforms, DOS47(TM) and Biphasix(TM) and the Company's current product development programs, L-DOS47 and Topical Interferon Alpha-2b.

L-DOS47 Product Development Update

Over the past quarter, Helix has continued to advance towards initiating Phase I/II-level human clinical studies with L-DOS47. It has submitted a formal meeting request to the FDA for a pre-IND meeting, in anticipation of a future IND filing. The Company has also continued to advance its GMP manufacturing scale-up program with the successful production of engineering batches of L-DOS47, and is currently making preparations to produce its first clinical batch of GMP product to be used in its initial human trials.

Helix plans to file IND/CTA applications in North America and Europe, respectively, to seek permission to initiate Phase I/II studies. Due to recent challenges in successfully producing GMP engineering batches to date, including third party scheduling and technical issues, the Company has revised its estimated date of IND filing. Based on the estimated delay for completing the remaining program activities, and assuming successful and timely completi
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... At the request of the AMA, the ... for the public comment period (Docket No. FAA-2014-0396) for ... established by Congress as part of the FAA Modernization ... the new deadline for comments as September 23, 2014. ... published in the Federal Register on July 25, 2014, ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Gain ... Global Supply Chain of the biotech industry. Nominations ... Innovation Awards, brought to you by the ... organization of supply chain management professionals for the ... to stakeholders of the Biotech industry – Manufacturers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, ... the emerging field of regenerative medicine, announced today ... a presentation to investors on Tuesday, July 29, ...  The presentation will include an overview of Asterias, ... the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least ...
Breaking Biology Technology:FAA Grants Comment Extension at the Request of AMA 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... the Georgia Institute of Technology have made important findings ... an electrical field on a surface-supported gold nanocluster changes ... flat structure. In another paper, they relate their discovery ... magnetic through oxygenation of gold nanowires. They also found ...
... ETEX Corporation, an advanced,biomaterials company, announced today that ... Health, Inc., Under the agreement, LifeNet Health ... to be mixed with ETEX,s proprietary,calcium phosphate to ... will manufacture EquivaBone(TM) in its Cambridge,facilities and market ...
... IOMI ) today announced that it will release fourth ... and hold a,conference call and live webcast to discuss ... 1:30 p.m. Eastern Time., Conference Call Details, ... 6 at 1:30 p.m.,Eastern Time via phone, please dial ...
Cached Biology Technology:Physicists discover gold can be magnetic on the nanoscale 2Physicists discover gold can be magnetic on the nanoscale 3Physicists discover gold can be magnetic on the nanoscale 4ETEX and LifeNet Health, Inc. Enter Agreement 2Iomai to Announce Fourth Quarter and Year-End 2007 Financial Results and Host Webcast on Thursday, March 6 2
(Date:7/28/2014)... wild relative of the domestic tomato, has been published ... headed by Professors Neelima Sinha and Julin Maloof at ... genome information may help breeders produce tastier, more stress-tolerant ... journal Nature Genetics , was lead by Bjrn ... UC Davis labs carried out work on the transcriptome ...
(Date:7/28/2014)... of a new study suggest two ways to effectively address ... well in obese women, compared to women of a normal ... method, researchers say, but as the population has increased in ... for obese women. Studies have consistently found that obesity has ... may in turn affect how well the pill prevents pregnancy. ...
(Date:7/28/2014)... Jude Children,s Research Hospital study found that 73 percent ... their risk of developing metabolic syndrome and related health ... results appear in the current issue of the journal ... 1,598 adult survivors of childhood cancer in the study ... factors like high blood pressure, abdominal obesity, elevated triglyceride ...
Breaking Biology News(10 mins):Strategies identified to improve oral contraceptive success with obese women 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... dominates a plant,s growth principally because it was there first, ... the plant. Collaborating teams from the University of ... Canada combined their expertise in molecular genetics and computational modelling ... encourages plants to thrive. Understanding of the action and ...
... , , , ... that a new market research report is available in its catalogue. ... Market , , http://www.reportlinker.com/p0119500/World-Dynamic-Signature-Verification-Market.html ... for Dynamic Signature Verification in US$ Thousands. The market for Dynamic ...
... RESTON, Virginia, September 17 WCC Smart Search ... for multi-modal fusion, today,announced that it has been selected ... their driver registration system. ELISE ID will be used,to ... existing databases,that contain over 20 million records. It will ...
Cached Biology News:Explaining why pruning encourages plants to thrive 2Reportlinker Adds World Dynamic Signature Verification Market Report 2Reportlinker Adds World Dynamic Signature Verification Market Report 3Reportlinker Adds World Dynamic Signature Verification Market Report 4Reportlinker Adds World Dynamic Signature Verification Market Report 5Reportlinker Adds World Dynamic Signature Verification Market Report 6Reportlinker Adds World Dynamic Signature Verification Market Report 7Reportlinker Adds World Dynamic Signature Verification Market Report 8Reportlinker Adds World Dynamic Signature Verification Market Report 9
Rabbit polyclonal to Testosterone 19 ( Abpromise for all tested applications). Antigen: Testosterone 19 CME HSA (Human)...
Kinase Buffer can be used to assay protein kinase activity...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
alpha/beta-Tubulin Antibody Ship: Hot Store: -20 C...
Biology Products: